Recently, Singh et al. [72] showed that DTX combined with thymoquinone induces apoptosis in prostate cancer cells via inhibition of the PI3 K/AKT signaling pathway, improving the survival rate and quality of life of prostate cancer patients. This evidence concerns the gene AKT1 and prostate carcinoma.